NAD+: Compound Profile

NAD+ is unusual among the subjects Nexara profiles: it is not a peptide but a coenzyme, one of the most heavily cited molecules in all of cellular metabolism. It is grouped here with the mitochondrial research subjects because the work that uses it concentrates on the same organelle. This profile covers what it is, the redox and enzyme-cofactor roles the literature attributes to it, and where it sits relative to the peptides that share its research territory. For the wider class, see the mitochondrial-targeted peptides overview.

What is NAD+?#

NAD+, or nicotinamide adenine dinucleotide, is a dinucleotide built from two nucleotides joined at their phosphate groups: one carries an adenine base, the other a nicotinamide base. That nicotinamide ring is the working end. It accepts a hydride ion to become the reduced form, NADH, then releases it again, which is how the molecule shuttles electrons between the reactions of central metabolism. The "+" in the name marks the positive charge on the nicotinamide nitrogen in the oxidized state. Because NAD+ is an endogenous coenzyme rather than a designed analog, its identity is fixed and well characterized; the reliable anchor here is its chemical database record rather than any supplier-specific figure.

What does the research literature study?#

The NAD+ literature runs along two threads. The first is its classical role as a redox cofactor: NAD+ and NADH move electrons through glycolysis, the citric acid cycle, and oxidative phosphorylation, which is why bioenergetics studies track the cellular NAD+/NADH ratio as a readout of metabolic state. The second thread, opened more recently, is NAD+ as a consumed substrate rather than a recycled carrier. Sirtuins, a family of enzymes first characterized as human homologs of the yeast Sir2 gene, cleave NAD+ as part of their deacetylase chemistry, and PARP DNA-repair enzymes consume it as well. A 2015 review in Science frames the field around this dual identity and its relevance to aging, metabolism, and neurodegeneration models.

Because cells cannot import NAD+ freely, much of the experimental work uses precursors that feed the salvage pathway. A molecular evaluation of the NAD+ precursors nicotinic acid, nicotinamide, and nicotinamide riboside maps how each enters that pathway. Preclinical studies then use those precursors as tools: nicotinamide riboside has been reported to raise NAD+ and enhance oxidative metabolism in mice, long-term nicotinamide mononucleotide administration has been studied in aging rodent models, and direct NAD+ repletion has been linked to mitochondrial and stem-cell function in animal work. All of this is preclinical research, conducted in cell culture and animal models, and does not speak to effects in people.

Where NAD+ sits among the mitochondrial research subjects#

The mitochondrial class Nexara tracks is about how a molecule relates to the organelle. SS-31 is a synthetic peptide that homes to a membrane lipid to act on the mitochondrion from outside; MOTS-c is a peptide encoded inside the mitochondrial genome that acts as an exported signal. NAD+ is a third relationship: not a peptide at all, but the coenzyme those bioenergetic reactions actually run on. It is the currency the class studies rather than a molecule that targets or originates from the organelle. That difference is why it reads as the odd member out, and why it is a useful reference point when reading the peptide profiles. The two routes to the organelle are unpacked in how mitochondrial-targeted peptides work.

Handling and storage#

NAD+ is supplied as a lyophilized solid and dissolved prior to use. It is a hygroscopic coenzyme that is less stable in solution than the dry powder, so the same handling discipline the peptide catalog uses applies: the reconstitution primer covers solvent selection and avoiding degradation on dissolution, while the cold-chain article covers how stability changes once the powder is in solution.

Sources and further reading#

• NAD+ in aging, metabolism, and neurodegeneration (PMID 26785480): a review framing NAD+ as both a redox cofactor and a consumed enzyme substrate. Science 2015.
• Characterization of five human cDNAs with homology to the yeast SIR2 gene (PMID 10381378): the primary identification of human Sir2-like proteins (sirtuins), the NAD+-consuming enzymes central to the newer NAD+ literature. Biochem Biophys Res Commun 1999.
• Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD+ precursors (PMID 18429699): a review mapping how the NAD+ precursors enter the salvage pathway. Annual Review of Nutrition 2008.
• The NAD+ precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity (PMID 22682224): a preclinical study of NAD+ repletion via a precursor in a mouse model. Cell Metabolism 2012.
• Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice (PMID 28068222): a rodent study of a NAD+ precursor across an aging cohort. Cell Metabolism 2016.
• NAD+ repletion improves mitochondrial and stem cell function and enhances life span in mice (PMID 27127236): an animal study linking NAD+ repletion to mitochondrial and stem-cell function. Science 2016.
• NAD+, PubChem CID 5892: chemical identity record for the coenzyme (molecular formula and structure).